🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalCanadian GLP-1 coverage — 12 month update

Canadian GLP-1 coverage — 12 month update

Dr.SleepRoch Tue, Dec 17, 2024 at 4:46 AM 52 replies 2,746 viewsPage 1 of 11
This thread is more than 17 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Dec 17, 2024 at 4:46 AM#1

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from the outside.

The bit I cannot resolve on my own is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.

Not looking for reassurance. Looking for the part I have got wrong.

15 18sarah_TO, wendy_avl, jason_paloalto and 12 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Dec 17, 2024 at 5:22 AM#2
Dr.SleepRoch said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…
Dr.SleepRoch said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

16 19PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 13 others
Reply Quote Save Share Report
TomFromTexas
Member
645
2,890
May 2024
Austin, TX
Dec 17, 2024 at 5:58 AM#3
Dr.MetabolicMD said:
Dr.SleepRoch said: ...regarding the discontinuation data for cost and coverage...

Financial impact of cost and coverage weight loss beyond medication cost:

  • Groceries: SAVED $281/month (eating less)
  • Restaurants: SAVED $211/month (fewer meals out)
  • Alcohol: SAVED $161/month (stopped drinking)
  • Life insurance: Premium REDUCED by $31/month (lower BMI)
  • Copays: SAVED $71/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

17 20Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 14 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Dec 17, 2024 at 6:34 AM#4
Dr.SleepRoch said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

This matches mine closely enough to be worth saying so out loud.

18 21GenomicsKate, Dr.ObesityMed, HealthEcon_DC and 15 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Dec 17, 2024 at 9:55 AM#5

Clinical perspective, offered as context rather than as advice.

Dr.SleepRoch said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

19 22kate.chem, DataDave, Dr.GutHealth and 16 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register